Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419166 | 0.83 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL16588889 | 0.80 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL2814577 | 0.79 | HSP90AB1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL15525977 | 0.75 | HSP90AB1 (0.56) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL14328376 | 0.75 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| Ganetespib SCHEMBL421080 | 0.74 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL421461 | 0.74 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL20287971 | 0.74 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1 | |
| SCHEMBL15526165 | 0.74 | HSP90AB1 (0.49) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL421467 | 0.74 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8993608-B2 | Method for inhibiting topoisomerase II | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
| WO-2008112199-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | HSP90AA1 8/4885HSP90AB1 6/4885HSP90B1 5/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | HSP90AA1 8/4885HSP90AB1 6/4885HSP90B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.